Applying these reported findings into current clinical practice remains however challenging given the increasing complex molecular landscape of AdvSM, the efficacy of KIT inhibitors such as midostaurin and avapritinib, and the continuous developments of transplant procedures, GvHD prophylaxis and supportive care strategies [18–20, 22–25, 34]. The gene discussed is KIT; the disease is graft versus host disease.